At present, 13 types of ADCs have been approved by the United States Food and Drug Administration (FDA), with over 200 additional ADCs at various stages of clinical trials.

In the field of tumor treatment, antibody-drug conjugates (ADCs) have the potential to enhance the efficacy and specificity of cancer therapy by combining monoclonal antibodies with potent cytotoxic drugs.